Insights on hospitalisations from the phase 3a COMBINE 1–3 trials of once-weekly IcoSema in individuals with type 2 diabetes: a post hoc analysis
Metabologia · 2026
DOI: 10.1007/s44357-026-00025-3 ↗Kurz gefasst
Fachartikel in der Zeitschrift Metabologia, 2026. Verfasst von Francesco Giorgino und 6 weiteren Autor:innen. Die Arbeit nennt 15 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Novo Nordisk A/S.
Themen: Diabetes mellitus
Abstract (Originalsprache)
Aims/hypothesis The COMBINE phase 3a trials evaluated the efficacy and safety of IcoSema, a once-weekly combination therapy of basal insulin icodec and semaglutide (a glucagon-like peptide-1 [GLP-1] analogue) in adults with type 2 diabetes. This post hoc analysis of the COMBINE 1–3 trials evaluated the impact of IcoSema during and around hospitalisation.
Methods
Across the COMBINE 1–3 trials, 2637 adults with type 2 diabetes received IcoSema or a comparator (insulin icodec; semaglutide 1.0 mg; or insulin glargine U100 + insulin aspart). Hospitalisation data were recorded through adverse event reports as part of safety monitoring. Upon trial completion, available data were used to assess: overall number and duration of hospitalisations; treatment discontinuation; IcoSema dose; HbA 1c levels; self-measured blood glucose levels; and number of hypoglycaemia episodes before, during and after hospitalisation.
Results
Across trials, 106/1325 participants receiving IcoSema and 92/1312 participants receiving a comparator were hospitalised. Median duration of hospital stay was 4.0 days with IcoSema and 5.0 days with comparators. Most hospitalised participants completed their trial without permanently discontinuing treatment (IcoSema 96.2%; comparators 93.5%). Mean IcoSema dose remained fairly stable before and after hospitalisation. Numerical reductions in mean HbA 1c levels and generally stable self-measured blood glucose values were observed during and around hospitalisation in both treatment groups. Three participants receiving IcoSema and eight participants receiving a comparator reported clinically significant or severe hypoglycaemia during hospitalisation. Conclusions/interpretation Post hoc findings suggest that IcoSema did not affect hospitalisation incidence or duration, and IcoSema dosing remained stable before and after hospitalisation. Hospitalisation did not have a negative impact on glycaemic control, and the number of hypoglycaemia episodes with IcoSema was low during hospitalisation.
Trial registration
COMBINE 1: ClinicalTrials.gov, NCT05352815 (registered 24 April 2022); COMBINE 2: ClinicalTrials.gov, NCT05259033 (registered 10 February 2022); COMBINE 3: ClinicalTrials.gov, NCT05013229 (registered 13 August 2021).
Förderung
- Novo Nordisk A/S
Zitieren
APA
Giorgino, F., Maltesen, R., Pletsch-Borba, L., Scavenius, C., Suzuki, R., Vianna, A. G. D., & Philis-Tsimikas, A. (2026). Insights on hospitalisations from the phase 3a COMBINE 1–3 trials of once-weekly IcoSema in individuals with type 2 diabetes: a post hoc analysis. Metabologia. https://doi.org/10.1007/s44357-026-00025-3
Vancouver
Giorgino F, Maltesen R, Pletsch-Borba L, Scavenius C, Suzuki R, Vianna AGD, et al. Insights on hospitalisations from the phase 3a COMBINE 1–3 trials of once-weekly IcoSema in individuals with type 2 diabetes: a post hoc analysis. Metabologia. 2026. doi:10.1007/s44357-026-00025-3
BibTeX
@article{Giorgino2026,
author = {Giorgino, Francesco and Maltesen, Raluca and Pletsch-Borba, Laura and Scavenius, Cathrine and Suzuki, Ryo and Vianna, André G. D. and Philis-Tsimikas, Athena},
title = {Insights on hospitalisations from the phase 3a COMBINE 1–3 trials of once-weekly IcoSema in individuals with type 2 diabetes: a post hoc analysis},
journal = {Metabologia},
year = {2026},
doi = {10.1007/s44357-026-00025-3}
}
EUVIMED